# Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

> **NCT00667654** · PHASE2 · COMPLETED · sponsor: **Centrexion Therapeutics** · enrollment: 54 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** CNTX-4975

## Key facts

- **NCT ID:** NCT00667654
- **Lead sponsor:** Centrexion Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-06
- **Final completion:** 2016-08
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667654, "Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00667654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*